A Randomised, Double-blind, Placebo-controlled Trial in Healthy Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 2.5 mg to 360 mg of BI 187004 CL
Latest Information Update: 09 Nov 2023
At a glance
- Drugs BI 187004 CL (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Sep 2023 Results constructing a population PK model to characterize the complex nonlinear PK behavior and perform simulation under different dosing regimens to facilitate the selection of optimal dosing regimens of BI187004, presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2012 New trial record